Hypermethylation in gastric cancer

Clinica Chimica Acta

Volumn 448, Issue , 2015, Pages 124-132

  Li, Yujun ^a   Liang, Junrong ^b   Hou, Peng ^a  

^a THE FIRST AFFILIATED HOSPITAL OF XI AN JIAOTONG UNIVERSITY   (China)

^b FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Biomarkers; Clinical utility; Epigenetics; Gastric cancer; Gene methylation

Indexed keywords

ANTINEOPLASTIC AGENT; AZACITIDINE; BIOLOGICAL MARKER; DECITABINE; DNA METHYLTRANSFERASE INHIBITOR; EPIGALLOCATECHIN GALLATE; FLAVONOID; GENISTEIN; HYDRALAZINE; PROCAINAMIDE; ZEBULARINE;

BODY FLUID; CANCER DIAGNOSIS; CANCER MORTALITY; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER THERAPY; COLON CANCER; DNA METHYLATION; EARLY DIAGNOSIS; EPIGENETICS; GENETIC ANALYSIS; GENOME ANALYSIS; HUMAN; LUNG CANCER; OVARY CANCER; PANCREAS CANCER; PRECANCER; PRIORITY JOURNAL; PROMOTER REGION; PROSTATE CANCER; REVIEW; STOMACH BIOPSY; STOMACH CANCER; STOMACH CARCINOGENESIS; TUMOR SUPPRESSOR GENE; ANIMAL; EPISTASIS; GENETICS; METABOLISM; STOMACH NEOPLASMS;

ANIMALS; DNA METHYLATION; EPISTASIS, GENETIC; HUMANS; STOMACH NEOPLASMS;

EID: 84936853874     PISSN: 00098981     EISSN: 18733492     Source Type: Journal    
DOI: 10.1016/j.cca.2015.07.001     Document Type: Review

References (149)

1. Qu Y., Dang S., Hou P. Gene methylation in gastric cancer. Clin. Chim. Acta 2013, 424:53-65.
2. Piazuelo M.B., Correa P. Gastric cancer: overview. Colomb. Med. (Cali) 2013, 44:192-201.
3. Kang C., Song J.J., Lee J., Kim M.Y. Epigenetics: an emerging player in gastric cancer. World J. Gastroenterol. 2014, 20:6433-6447.
4. Wang Y., Leung F.C. An evaluation of new criteria for CpG islands in the human genome as gene markers. Bioinformatics 2004, 20:1170-1177.
5. Bird A. DNA methylation patterns and epigenetic memory. Genes Dev. 2002, 16:6-21.
6. Guilford P., Humar B., Blair V. Hereditary diffuse gastric cancer: translation of CDH1 germline mutations into clinical practice. Gastric Cancer 2010, 13:1-10.
7. Kume K. Endoscopic therapy for early gastric cancer: standard techniques and recent advances in ESD. World J. Gastroenterol. 2014, 20:6425-6432.
8. Das P.M., Singal R. DNA methylation and cancer. J. Clin. Oncol. 2004, 22:4632-4642.
9. Jones P.A., Baylin S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3:415-428.
10. Leonhardt H., Page A.W., Weier H.U., Bestor T.H. A targeting sequence directs DNA methyltransferase to sites of DNA replication in mammalian nuclei. Cell 1992, 71:865-873.
11. Bestor T.H. Activation of mammalian DNA methyltransferase by cleavage of a Zn binding regulatory domain. EMBO J. 1992, 11:2611-2617.
12. Okano M., Bell D.W., Haber D.A., Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell 1999, 99:247-257.
13. Chen T., Ueda Y., Dodge J.E., Wang Z., Li E. Establishment and maintenance of genomic methylation patterns in mouse embryonic stem cells by Dnmt3a and Dnmt3b. Mol. Cell. Biol. 2003, 23:5594-5605.
14. Gowher H., Liebert K., Hermann A., Xu G., Jeltsch A. Mechanism of stimulation of catalytic activity of Dnmt3A and Dnmt3B DNA-(cytosine-C5)-methyltransferases by Dnmt3L. J. Biol. Chem. 2005, 280:13341-13348.
15. Takusagawa F., Kamitori S., Markham G.D. Structure and function of S-adenosylmethionine synthetase: crystal structures of S-adenosylmethionine synthetase with ADP, BrADP, and PPi at 28 angstroms resolution. Biochemistry (US) 1996, 35:2586-2596.
16. Robertson K.D. DNA methylation, methyltransferases, and cancer. Oncogene 2001, 20:3139-3155.
17. Jones P.A., Laird P.W. Cancer epigenetics comes of age. Nat. Genet. 1999, 21:163-167.
18. Singal R., Ginder G.D. DNA methylation. Blood 1999, 93:4059-4070.
19. Kass S.U., Pruss D., Wolffe A.P. How does DNA methylation repress transcription?. Trends Genet. 1997, 13:444-449.
20. Niwa T., Tsukamoto T., Toyoda T., et al. Inflammatory processes triggered by Helicobacter pylori infection cause aberrant DNA methylation in gastric epithelial cells. Cancer Res. 2010, 70:1430-1440.
21. Yuasa Y., Nagasaki H., Akiyama Y., et al. DNA methylation status is inversely correlated with green tea intake and physical activity in gastric cancer patients. Int. J. Cancer 2009, 124:2677-2682.
22. Issa J.P., Ahuja N., Toyota M., Bronner M.P., Brentnall T.A. Accelerated age-related CpG island methylation in ulcerative colitis. Cancer Res. 2001, 61:3573-3577.
23. Rang F.J., Boonstra J. Causes and consequences of age-related changes in DNA methylation: a role for ROS?. Biology (Basel) 2014, 3:403-425.
24. Fan W., Luo J. SIRT1 regulates UV-induced DNA repair through deacetylating XPA. Mol. Cell 2010, 39:247-258.
25. Espada J., Ballestar E., Santoro R., et al. Epigenetic disruption of ribosomal RNA genes and nucleolar architecture in DNA methyltransferase 1 (Dnmt1) deficient cells. Nucleic Acids Res. 2007, 35:2191-2198.
26. Fang M.Z., Wang Y., Ai N., et al. Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. Cancer Res. 2003, 63:7563-7570.
27. Fang M., Chen D., Yang C.S. Dietary polyphenols may affect DNA methylation. J. Nutr. 2007, 137:223S-228S.
28. Lambert J.D., Lee M.J., Diamond L., et al. Dose-dependent levels of epigallocatechin-3-gallate in human colon cancer cells and mouse plasma and tissues. Drug Metab. Dispos. 2006, 34:8-11.
29. Link A., Balaguer F., Goel A. Cancer chemoprevention by dietary polyphenols: promising role for epigenetics. Biochem. Pharmacol. 2010, 80:1771-1792.
30. Adlercreutz H., Mazur W. Phyto-oestrogens and Western diseases. Ann. Med. 1997, 29:95-120.
31. Cox R., Goorha S. A study of the mechanism of selenite-induced hypomethylated DNA and differentiation of Friend erythroleukemic cells. Carcinogenesis 1986, 7:2015-2018.
32. Fiala E.S., Staretz M.E., Pandya G.A., El-Bayoumy K., Hamilton S.R. Inhibition of DNA cytosine methyltransferase by chemopreventive selenium compounds, determined by an improved assay for DNA cytosine methyltransferase and DNA cytosine methylation. Carcinogenesis 1998, 19:597-604.
33. Anderson O.S., Sant K.E., Dolinoy D.C. Nutrition and epigenetics: an interplay of dietary methyl donors, one-carbon metabolism and DNA methylation. J. Nutr. Biochem. 2012, 23:853-859.
34. Sjodahl K., Jia C., Vatten L., Nilsen T., Hveem K., Lagergren J. Body mass and physical activity and risk of gastric cancer in a population-based cohort study in Norway. Cancer Epidemiol. Biomarkers Prev. 2008, 17:135-140.
35. Campbell P.T., Sloan M., Kreiger N. Physical activity and stomach cancer risk: the influence of intensity and timing during the lifetime. Eur. J. Cancer 2007, 43:593-600.
36. Zhang F.F., Cardarelli R., Carroll J., et al. Physical activity and global genomic DNA methylation in a cancer-free population. Epigenetics 2011, 6:293-299.
37. McGee S.L., Fairlie E., Garnham A.P., Hargreaves M. Exercise-induced histone modifications in human skeletal muscle. J. Physiol. 2009, 587:5951-5958.
38. Radom-Aizik S., Zaldivar F., Oliver S., Galassetti P., Cooper D.M. Evidence for microRNA involvement in exercise-associated neutrophil gene expression changes. J. Appl. Physiol. 2010, 109:252-261.
39. Eads C.A., Lord R.V., Kurumboor S.K., et al. Fields of aberrant CpG island hypermethylation in Barrett's esophagus and associated adenocarcinoma. Cancer Res. 2000, 60:5021-5026.
40. Maekita T., Nakazawa K., Mihara M., et al. High levels of aberrant DNA methylation in Helicobacter pylori-infected gastric mucosae and its possible association with gastric cancer risk. Clin. Cancer Res. 2006, 12:989-995.
41. Kang G.H., Lee H.J., Hwang K.S., Lee S., Kim J.H., Kim J.S. Aberrant CpG island hypermethylation of chronic gastritis, in relation to aging, gender, intestinal metaplasia, and chronic inflammation. Am. J. Pathol. 2003, 163:1551-1556.
42. Ushijima T., Okochi-Takada E. Aberrant methylations in cancer cells: where do they come from?. Cancer Sci. 2005, 96:206-211.
43. Llorent L., Richaud-Patin Y., Alcocer-Castillejos N., et al. Cytokine gene expression in cirrhotic and non-cirrhotic human liver. J. Hepatol. 1996, 24:555-563.
44. Cappello M., Keshav S., Prince C., Jewell D.P., Gordon S. Detection of mRNAs for macrophage products in inflammatory bowel disease by in situ hybridisation. Gut 1992, 33:1214-1219.
45. Mihm S., Fayyazi A., Ramadori G. Hepatic expression of inducible nitric oxide synthase transcripts in chronic hepatitis C virus infection: relation to hepatic viral load and liver injury. Hepatology 1997, 26:451-458.
46. McLaughlan J.M., Seth R., Vautier G., et al. Interleukin-8 and inducible nitric oxide synthase mRNA levels in inflammatory bowel disease at first presentation. J. Pathol. 1997, 181:87-92.
47. Matsusaka K., Funata S., Fukayama M., Kaneda A. DNA methylation in gastric cancer, related to Helicobacter pylori and Epstein-Barr virus. World J. Gastroenterol. 2014, 20:3916-3926.
48. Yamashita S., Tsujino Y., Moriguchi K., Tatematsu M., Ushijima T. Chemical genomic screening for methylation-silenced genes in gastric cancer cell lines using 5-aza-2'-deoxycytidine treatment and oligonucleotide microarray. Cancer Sci. 2006, 97:64-71.
49. Chan A.O., Peng J.Z., Lam S.K., et al. Eradication of Helicobacter pylori infection reverses E-cadherin promoter hypermethylation. Gut 2006, 55:463-468.
50. Sepulveda A.R., Yao Y., Yan W., et al. CpG methylation and reduced expression of O6-methylguanine DNA methyltransferase is associated with Helicobacter pylori infection. Gastroenterology 2010, 138:1836-1844.
51. Forman D., Webb P., Parsonnet J. H. pylori and gastric cancer. Lancet 1994, 343:243-244.
52. Uemura N., Okamoto S., Yamamoto S., et al. Helicobacter pylori infection and the development of gastric cancer. N. Engl. J. Med. 2001, 345:784-789.
53. Hur K., Niwa T., Toyoda T., et al. Insufficient role of cell proliferation in aberrant DNA methylation induction and involvement of specific types of inflammation. Carcinogenesis 2011, 32:35-41.
54. Niwa T., Ushijima T. Induction of epigenetic alterations by chronic inflammation and its significance on carcinogenesis. Adv. Genet. 2010, 71:41-56.
55. Nardone G., Rocco A., Malfertheiner P. Review article: Helicobacter pylori and molecular events in precancerous gastric lesions. Aliment. Pharmacol. Ther. 2004, 20:261-270.
56. Sudo M., Chong J.M., Sakuma K., et al. Promoter hypermethylation of E-cadherin and its abnormal expression in Epstein-Barr virus-associated gastric carcinoma. Int. J. Cancer 2004, 109:194-199.
57. Osawa T., Chong J.M., Sudo M., et al. Reduced expression and promoter methylation of p16 gene in Epstein-Barr virus-associated gastric carcinoma. Jpn. J. Cancer Res. 2002, 93:1195-1200.
58. Ryan J.L., Jones R.J., Kenney S.C., et al. Epstein-Barr virus-specific methylation of human genes in gastric cancer cells. Infect. Agents Cancer 2010, 5:27.
59. Kaneda A., Matsusaka K., Aburatani H., Fukayama M. Epstein-Barr virus infection as an epigenetic driver of tumorigenesis. Cancer Res. 2012, 72:3445-3450.
60. Cho B., Lee H., Jeong S., et al. Promoter hypomethylation of a novel cancer/testis antigen gene CAGE is correlated with its aberrant expression and is seen in premalignant stage of gastric carcinoma. Biochem. Biophys. Res. Commun. 2003, 307:52-63.
61. Kim T.Y., Lee H.J., Hwang K.S., et al. Methylation of RUNX3 in various types of human cancers and premalignant stages of gastric carcinoma. Lab. Investig. 2004, 84:479-484.
62. Zheng Z.H., Sun X.J., Ma M.C., Hao D.M., Liu Y.H., Sun K.L. Studies of promoter methylation status and protein expression of E-cadherin gene in associated progression stages of gastric cancer. Yi Chuan Xue Bao 2003, 30:103-108.
63. Wang L.H., Choi Y.L., Hua X.Y., et al. Increased expression of sonic hedgehog and altered methylation of its promoter region in gastric cancer and its related lesions. Mod. Pathol. 2006, 19:675-683.
64. Park S.Y., Yoo E.J., Cho N.Y., Kim N., Kang G.H. Comparison of CpG island hypermethylation and repetitive DNA hypomethylation in premalignant stages of gastric cancer, stratified for Helicobacter pylori infection. J. Pathol. 2009, 219:410-416.
65. Ushijima T., Nakajima T., Maekita T. DNA methylation as a marker for the past and future. J. Gastroenterol. 2006, 41:401-407.
66. Kusano M., Toyota M., Suzuki H., et al. Genetic, epigenetic, and clinicopathologic features of gastric carcinomas with the CpG island methylator phenotype and an association with Epstein-Barr virus. Cancer 2006, 106:1467-1479.
67. Kaneda A., Kaminishi M., Yanagihara K., Sugimura T., Ushijima T. Identification of silencing of nine genes in human gastric cancers. Cancer Res. 2002, 62:6645-6650.
68. Oue N., Oshimo Y., Nakayama H., et al. DNA methylation of multiple genes in gastric carcinoma: association with histological type and CpG island methylator phenotype. Cancer Sci. 2003, 94:901-905.
69. Oue N., Mitani Y., Motoshita J., et al. Accumulation of DNA methylation is associated with tumor stage in gastric cancer. Cancer 2006, 106:1250-1259.
70. Kang G.H., Lee S., Cho N.Y., et al. DNA methylation profiles of gastric carcinoma characterized by quantitative DNA methylation analysis. Lab. Investig. 2008, 88:161-170.
71. Tamura G., Maesawa C., Suzuki Y., et al. Mutations of the APC gene occur during early stages of gastric adenoma development. Cancer Res. 1994, 54:1149-1151.
72. Nakatsuru S., Yanagisawa A., Ichii S., et al. Somatic mutation of the APC gene in gastric cancer: frequent mutations in very well differentiated adenocarcinoma and signet-ring cell carcinoma. Hum. Mol. Genet. 1992, 1:559-563.
73. Mayer B., Johnson J.P., Leitl F., et al. E-cadherin expression in primary and metastatic gastric cancer: down-regulation correlates with cellular dedifferentiation and glandular disintegration. Cancer Res. 1993, 53:1690-1695.
74. Chan A.O., Lam S.K., Wong B.C., et al. Promoter methylation of E-cadherin gene in gastric mucosa associated with Helicobacter pylori infection and in gastric cancer. Gut 2003, 52:502-506.
75. Graziano F., Arduini F., Ruzzo A., et al. Combined analysis of E-cadherin gene (CDH1) promoter hypermethylation and E-cadherin protein expression in patients with gastric cancer: implications for treatment with demethylating drugs. Ann. Oncol. 2004, 15:489-492.
76. Ichikawa D., Koike H., Ikoma H., et al. Detection of aberrant methylation as a tumor marker in serum of patients with gastric cancer. Anticancer Res. 2004, 24:2477-2481.
77. Van De Voorde L., Speeckaert R., Van Gestel D., et al. DNA methylation-based biomarkers in serum of patients with breast cancer. Mutat. Res. 2012, 751:304-325.
78. Lu X.X., Yu J.L., Ying L.S., et al. Stepwise cumulation of RUNX3 methylation mediated by Helicobacter pylori infection contributes to gastric carcinoma progression. Cancer 2012, 118:5507-5517.
79. Li W.Q., Pan K.F., Zhang Y., et al. RUNX3 methylation and expression associated with advanced precancerous gastric lesions in a Chinese population. Carcinogenesis 2011, 32:406-410.
80. Wang Y.C., Yu Z.H., Liu C., et al. Detection of RASSF1A promoter hypermethylation in serum from gastric and colorectal adenocarcinoma patients. World J. Gastroenterol. 2008, 14:3074-3080.
81. Abbaszadegan M.R., Moaven O., Sima H.R., et al. p16 promoter hypermethylation: a useful serum marker for early detection of gastric cancer. World J. Gastroenterol. 2008, 14:2055-2060.
82. Sapari N.S., Loh M., Vaithilingam A., Soong R. Clinical potential of DNA methylation in gastric cancer: a meta-analysis. PLoS One 2012, 7:e36275.
83. Watanabe Y., Kim H.S., Castoro R.J., et al. Sensitive and specific detection of early gastric cancer with DNA methylation analysis of gastric washes. Gastroenterology 2009, 136:2149-2158.
84. Gros C., Fahy J., Halby L., et al. DNA methylation inhibitors in cancer: recent and future approaches. Biochimie 2012, 94:2280-2296.
85. Santi D.V., Norment A., Garrett C.E. Covalent bond formation between a DNA-cytosine methyltransferase and DNA containing 5-azacytosine. Proc. Natl. Acad. Sci. U. S. A. 1984, 81:6993-6997.
86. Decitabine: 2'-deoxy-5-azacytidine, Aza dC, DAC, dezocitidine, NSC 127716. Drugs R D 2003, 4:352-358.
87. Meng C.F., Zhu X.J., Dai D.Q., Peng G. Effects of 5-Aza-2'-deoxycytidine and trichostatin A on P16, hMLH1 and MGMT genes and DNA methylation in human gastric cancer cells. Zhonghua Wei Chang Wai Ke Za Zhi 2009, 12:494-497.
88. Niwa T., Toyoda T., Tsukamoto T., Mori A., Tatematsu M., Ushijima T. Prevention of Helicobacter pylori-induced gastric cancers in gerbils by a DNA demethylating agent. Cancer Prev. Res. (Phila.) 2013, 6:263-270.
89. Schroeder G.K., Zhou L., Snider M.J., Chen X., Wolfenden R. Flight of a cytidine deaminase complex with an imperfect transition state analogue inhibitor: mass spectrometric evidence for the presence of a trapped water molecule. Biochemistry (US) 2012, 51:6476-6486.
90. Zhou L., Cheng X., Connolly B.A., Dickman M.J., Hurd P.J., Hornby D.P. Zebularine: a novel DNA methylation inhibitor that forms a covalent complex with DNA methyltransferases. J. Mol. Biol. 2002, 321:591-599.
91. Tan W., Zhou W., Yu H.G., Luo H.S., Shen L. The DNA methyltransferase inhibitor zebularine induces mitochondria-mediated apoptosis in gastric cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2013, 430:250-255.
92. Cheng J.C., Yoo C.B., Weisenberger D.J., et al. Preferential response of cancer cells to zebularine. Cancer Cell 2004, 6:151-158.
93. Cornacchia E., Golbus J., Maybaum J., Strahler J., Hanash S., Richardson B. Hydralazine and procainamide inhibit T cell DNA methylation and induce autoreactivity. J. Immunol. 1988, 140:2197-2200.
94. Segura-Pacheco B., Trejo-Becerril C., Perez-Cardenas E., et al. Reactivation of tumor suppressor genes by the cardiovascular drugs hydralazine and procainamide and their potential use in cancer therapy. Clin. Cancer Res. 2003, 9:1596-1603.
95. Villar-Garea A., Fraga M.F., Espada J., Esteller M. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res. 2003, 63:4984-4989.
96. Lee B.H., Yegnasubramanian S., Lin X., Nelson W.G. Procainamide is a specific inhibitor of DNA methyltransferase 1. J. Biol. Chem. 2005, 280:40749-40756.
97. Stresemann C., Brueckner B., Musch T., Stopper H., Lyko F. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res. 2006, 66:2794-2800.
98. Halby L., Champion C., Senamaud-Beaufort C., et al. Rapid synthesis of new DNMT inhibitors derivatives of procainamide. Chembiochem 2012, 13:157-165.
99. Fang M.Z., Chen D., Sun Y., Jin Z., Christman J.K., Yang C.S. Reversal of hypermethylation and reactivation of p16INK4a, RARbeta, and MGMT genes by genistein and other isoflavones from soy. Clin. Cancer Res. 2005, 11:7033-7041.
100. Chuang J.C., Yoo C.B., Kwan J.M., et al. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2'-deoxycytidine. Mol. Cancer Ther. 2005, 4:1515-1520.
101. Wang Y., Li Y., Liu X., Cho W.C. Genetic and epigenetic studies for determining molecular targets of natural product anticancer agents. Curr. Cancer Drug Targets 2013, 13:506-518.
102. Lee W.J., Shim J.Y., Zhu B.T. Mechanisms for the inhibition of DNA methyltransferases by tea catechins and bioflavonoids. Mol. Pharmacol. 2005, 68:1018-1030.
103. Xu L., Li X., Chu E.S., et al. Epigenetic inactivation of BCL6B, a novel functional tumour suppressor for gastric cancer, is associated with poor survival. Gut 2012, 61:977-985.
104. Yu J., Cheng Y.Y., Tao Q., et al. Methylation of protocadherin 10, a novel tumor suppressor, is associated with poor prognosis in patients with gastric cancer. Gastroenterology 2009, 136:640-651.
105. Wanajo A., Sasaki A., Nagasaki H., et al. Methylation of the calcium channel-related gene, CACNA2D3, is frequent and a poor prognostic factor in gastric cancer. Gastroenterology 2008, 135:580-590.
106. Yu J., Tao Q., Cheng Y.Y., et al. Promoter methylation of the Wnt/beta-catenin signaling antagonist Dkk-3 is associated with poor survival in gastric cancer. Cancer 2009, 115:49-60.
107. Wang L., Wang X., Wang X., et al. Klotho is silenced through promoter hypermethylation in gastric cancer. Am. J. Cancer Res. 2011, 1:111-119.
108. Shi J., Zhang G., Yao D., et al. Prognostic significance of aberrant gene methylation in gastric cancer. Am. J. Cancer Res. 2012, 2:116-129.
109. Yao D., Shi J., Shi B., et al. Quantitative assessment of gene methylation and their impact on clinical outcome in gastric cancer. Clin. Chim. Acta 2012, 413:787-794.
110. Sugita H., Iida S., Inokuchi M., et al. Methylation of BNIP3 and DAPK indicates lower response to chemotherapy and poor prognosis in gastric cancer. Oncol. Rep. 2011, 25:513-518.
111. Li M., Chen W.D., Papadopoulos N., et al. Sensitive digital quantification of DNA methylation in clinical samples. Nat. Biotechnol. 2009, 27:858-863.
112. Tahiliani M., Koh K.P., Shen Y., et al. Conversion of 5-methylcytosine to 5-hydroxymethylcytosine in mammalian DNA by MLL partner TET1. Science 2009, 324:930-935.
113. Huang Y., Pastor W.A., Shen Y., Tahiliani M., Liu D.R., Rao A. The behaviour of 5-hydroxymethylcytosine in bisulfite sequencing. PLoS One 2010, 5:e8888.
114. Ikoma H., Ichikawa D., Koike H., et al. Correlation between serum DNA methylation and prognosis in gastric cancer patients. Anticancer Res. 2006, 26:2313-2316.
115. Lee T.L., Leung W.K., Chan M.W., et al. Detection of gene promoter hypermethylation in the tumor and serum of patients with gastric carcinoma. Clin. Cancer Res. 2002, 8:1761-1766.
116. Zhang X., Zhang X., Sun B., et al. Detection of aberrant promoter methylation of RNF180, DAPK1 and SFRP2 in plasma DNA of patients with gastric cancer. Oncol. Lett. 2014, 8:1745-1750.
117. Wani M., Afroze D., Makhdoomi M., et al. Promoter methylation status of DNA repair gene (hMLH1) in gastric carcinoma patients of the Kashmir valley. Asian Pac. J. Cancer Prev. 2012, 13:4177-4181.
118. Xiong H.L., Liu X.Q., Sun A.H., He Y., Li J., Xia Y. Aberrant DNA methylation of P16, MGMT, hMLH1 and hMSH2 genes in combination with the MTHFR C677T genetic polymorphism in gastric cancer. Asian Pac. J. Cancer Prev. 2013, 14:3139-3142.
119. Mir M.R., Shabir N., Wani K.A., et al. Association between p16, hMLH1 and E-cadherin promoter hypermethylation and intake of local hot salted tea and sun-dried foods in Kashmiris with gastric tumors. Asian Pac. J. Cancer Prev. 2012, 13:181-186.
120. Cheung K.F., Lam C.N., Wu K., et al. Characterization of the gene structure, functional significance, and clinical application of RNF180, a novel gene in gastric cancer. Cancer 2012, 118:947-959.
121. Hiraki M., Kitajima Y., Koga Y., et al. Aberrant gene methylation is a biomarker for the detection of cancer cells in peritoneal wash samples from advanced gastric cancer patients. Ann. Surg. Oncol. 2011, 18:3013-3019.
122. Kinoshita T., Nomoto S., Kodera Y., Koike M., Fujiwara M., Nakao A. Decreased expression and aberrant hypermethylation of the SFRP genes in human gastric cancer. Hepatogastroenterology 2011, 58:1051-1056.
123. Cheng Y.Y., Yu J., Wong Y.P., et al. Frequent epigenetic inactivation of secreted frizzled-related protein 2 (SFRP2) by promoter methylation in human gastric cancer. Br. J. Cancer 2007, 97:895-901.
124. Nojima M., Suzuki H., Toyota M., et al. Frequent epigenetic inactivation of SFRP genes and constitutive activation of Wnt signaling in gastric cancer. Oncogene 2007, 26:4699-4713.
125. Feng G., Zhang Y., Yuan H., et al. DNA methylation of trefoil factor 1 (TFF1) is associated with the tumorigenesis of gastric carcinoma. Mol. Med. Rep. 2014, 9:109-117.
126. Takada H., Imoto I., Tsuda H., et al. ADAM23, a possible tumor suppressor gene, is frequently silenced in gastric cancers by homozygous deletion or aberrant promoter hypermethylation. Oncogene 2005, 24:8051-8060.
127. Yang M., Kim H.S., Cho M.Y. Different methylation profiles between intestinal and diffuse sporadic gastric carcinogenesis. Clin. Res. Hepatol. Gastroenterol. 2014, 38:613-620.
128. Watanabe Y., Toyota M., Kondo Y., et al. PRDM5 identified as a target of epigenetic silencing in colorectal and gastric cancer. Clin. Cancer Res. 2007, 13:4786-4794.
129. Shin D.Y., Sung K.H., Kim G.Y., Kim W.J., Yoo Y.H., Choi Y.H. Decitabine, a DNA methyltransferases inhibitor, induces cell cycle arrest at G2/M phase through p53-independent pathway in human cancer cells. Biomed. Pharmacother. 2013, 67:305-311.
130. Murai M., Toyota M., Suzuki H., et al. Aberrant methylation and silencing of the BNIP3 gene in colorectal and gastric cancer. Clin. Cancer Res. 2005, 11:1021-1027.
131. Hu S.L., Kong X.Y., Cheng Z.D., et al. Promoter methylation of p16, Runx3, DAPK and CHFR genes is frequent in gastric carcinoma. Tumori 2010, 96:726-733.
132. Li Z., Chim J.C., Yang M., Ye J., Wong B.C., Qiao L. Role of PCDH10 and its hypermethylation in human gastric cancer. Biochim. Biophys. Acta 2012, 1823:298-305.
133. Chan A.O. E-cadherin in gastric cancer. World J. Gastroenterol. 2006, 12:199-203.
134. Christofori G., Semb H. The role of the cell-adhesion molecule E-cadherin as a tumour-suppressor gene. Trends Biochem. Sci. 1999, 24:73-76.
135. Bashash M., Shah A., Hislop G., et al. Genetic polymorphisms at TIMP3 are associated with survival of adenocarcinoma of the gastroesophageal junction. PLoS One 2013, 8:e59157.
136. Guan Z., Zhang J., Song S., Dai D. Promoter methylation and expression of TIMP3 gene in gastric cancer. Diagn. Pathol. 2013, 8:110.
137. Ma J.M., Shi Z.J., Chen L., et al. Expression of multiple tumor suppressor gene p16 and its relationship with prognosis of gastric cancer patients. Zhonghua Zhong Liu Za Zhi 2012, 34:21-25.
138. do N.B.B., Burbano R.M., Harada M.L. Analysis of the methylation patterns of the p16 INK4A, p15 INK4B, and APC genes in gastric adenocarcinoma patients from a Brazilian population. Tumour Biol. 2013, 34:2127-2133.
139. Sakellariou S., Liakakos T., Ghiconti I., Hadjikokolis S., Nakopoulou L., Pavlakis K. Immunohistochemical expression of P15 (INK4B) and SMAD4 in advanced gastric cancer. Anticancer Res. 2008, 28:1079-1083.
140. Jin J., Xie L., Xie C.H., Zhou Y.F. Aberrant DNA methylation of MGMT and hMLH1 genes in prediction of gastric cancer. Genet. Mol. Res. 2014, 13:4140-4145.
141. Yang Q., Shao Y., Shi J., et al. Concomitant PIK3CA amplification and RASSF1A or PAX6 hypermethylation predict worse survival in gastric cancer. Clin. Biochem. 2014, 47:111-116.
142. Zhou S.L., Cui J., Fan Z.M., et al. Polymorphism of A133S and promoter hypermethylation in Ras association domain family 1A gene (RASSF1A) is associated with risk of esophageal and gastric cardia cancers in Chinese population from high incidence area in northern China. BMC Cancer 2013, 13:259.
143. Luo D., Ye T., Li T.Q., et al. Ectopic expression of RASSF2 and its prognostic role for gastric adenocarcinoma patients. Exp. Ther. Med. 2012, 3:391-396.
144. Wu Q., Zhang M., Liu S., Chen Y., Su W. Retinoic acid receptor beta is required for anti-activator protein-1 activity by retinoic acid in gastric cancer cells. Chin. Med. J. (Engl.) 2002, 115:810-814.
145. Hu K.W., Chen F.H., Ge J.F., Cao L.Y., Li H. Retinoid receptors in gastric cancer: expression and influence on prognosis. Asian Pac. J. Cancer Prev. 2012, 13:1809-1817.
146. Hong H., Zhou K., Fu P., et al. Relationship between promoter methylation of Syk and Runx3 genes and postoperative recurrence and metastasis in gastric carcinoma. Zhonghua Zhong Liu Za Zhi 2014, 36:341-345.
147. Sakakura C., Hagiwara A., Miyagawa K., et al. Frequent downregulation of the runt domain transcription factors RUNX1, RUNX3 and their cofactor CBFB in gastric cancer. Int. J. Cancer 2005, 113:221-228.
148. Hayashi T., Asano H., Toyooka S., et al. DNA methylation status of REIC/Dkk-3 gene in human malignancies. J. Cancer Res. Clin. Oncol. 2012, 138:799-809.
149. Deng J., Liang H., Dong Q., et al. The survival decrease in gastric cancer is associated with the methylation of B-cell CLL/lymphoma 6 member B promoter. Open Biol. 2014, 4.